Prime Medicine (PRME) vs Solid Biosciences (SLDB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Solid Biosciences (SLDB) has outperformed Prime Medicine (PRME) over the past year, gaining 8.1% versus a loss of 44.5%. Solid Biosciences is the larger company by market cap ($731.3 million vs $649.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRME | SLDB |
|---|---|---|
| Share price | $3.58 | $6.82 |
| Market cap | $649.33M | $731.28M |
| 1-day change | -8.21% | -0.44% |
| YTD return | +3.17% | +20.92% |
| 1-year return | -44.50% | +8.08% |
| 5-year return | — | -79.79% |
| EPS (TTM) | $-1.07 | $-1.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.65 | $11.45 |
| 52-week low | $2.67 | $3.79 |
| Distance from 52-week high | -46.17% | -40.44% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +98.60% | +173.02% |
| Average volume | 3.32M | 1.09M |
| Shares outstanding | 181.38M | 107.23M |
| Employees | 146 | 121 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLDB has outperformed PRME by 52.6 percentage points over the past year.
About Prime Medicine
PRME stock →Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 146 employees
About Solid Biosciences
SLDB stock →Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 121 employees
PRME vs SLDB FAQ
Which is bigger, Prime Medicine or Solid Biosciences?
Solid Biosciences (SLDB) is larger, with a market capitalization of $731.28M compared with $649.33M for Prime Medicine (PRME).
Which stock has performed better over the past year, PRME or SLDB?
SLDB returned +8.08% over the past 12 months, compared with -44.50% for PRME (price return, excluding dividends). Past performance does not predict future results.
Are Prime Medicine and Solid Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.